Annual report [Section 13 and 15(d), not S-K Item 405]

Accounts Payable and Accrued Expenses (Tables)

v3.25.1
Accounts Payable and Accrued Expenses (Tables)
12 Months Ended
Dec. 31, 2024
Accounts Payable and Accrued Expenses  
Schedule of Accounts Payable and Accrued Expenses

December 31,

($ in thousands)

2024

    

2023

Accounts payable

$

7,464

$

6,322

Accrued research and development

330

4,118

Accrued compensation

93

2,838

Other (1)

1,599

739

Total accounts payable and accrued expenses

$

9,486

$

14,017

(1) Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5.